What are you searching for?

05.07.2022 | Tracker

Product Launch Tracker: HCPs discuss approvals including for the prevention of smallpox and monkeypox.

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout July 2022 we tracked the global conversations of 1,836 HCPs who posted 2,413 English-language Twitter posts about the launches and approvals of new products.

A graph showing HCP mentions of product launches in July 2022

Across the month of July, HCPs commented on and shared the news of several product approvals across various indications including type II diabetes, vitiligo and ALK-positive tumours. Additionally, HCPs also held discussions around the approval of treatments for monkeypox, as well as a recently published review of all newly approved FDA treatments from 2021, assessing the human genetics evidence for each approval.

The recent outbreak of monkeypox currently affecting many countries has led to HCPs discussing regulatory bodies stances on several treatment options for the disease. Initially on the 14th July several HCPs made comments on the lack of availability or access to TPOXX (tecovirimat) for those suffering from monkeypox, despite it already being an FDA approved drug.

 

Later in the month, 19 HCPs also shared the FDA’s news that they had approved a supplement to the biologics licence for the Jynneos vaccine, manufactured by Bavarian Nordic, in order to allow for increased manufacturing of the monkeypox vaccine.

HCPs also shared the approval of Incyte’s Opzelura (ruxolitinib) cream for the treatment of non segmental vitiligo in adults and paediatric patients 12 years of age and older. Opzelura is the first ever home drug that can reverse skin pigmentation. HCPs were positive about the approval and described it as exciting progress for the therapy area.

Another approval which caught HCPs attention in July was Xalkori (crizotinib, Pfizer), which the FDA approved for adult and paediatric patients with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumours (IMT). When sharing the news of this approval HCPs chose to draw attention to the journey the drug had taken from the CREATE trial four years ago to its recent approval; while others celebrated the power of precision medicine demonstrated by the approval.

Additionally, HCPs also shared the marketing authorisation granted by the European Commission for Mounjaro, a treatment for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Endocrinologist Cristobal Morales played a key role in sharing the news of this approval, with 21 HCPs sharing his post.

Finally, HCPs also discussed the success of genetics informed drug discovery. One of the tenets of “personalised medicine” is that medications will be tailored to individuals based on their personalised genetics. Last year, the U.S. Food and Drug Administration’s Centre for Drug Evaluation and Research approved 50 drugs. A new study found that 33, or 66% of the approved drugs, were supported with genomic data, a statistic which many HCPs were impressed with.

The three most shared links from HCPs discussing product launches in June were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal

Methodology

  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 July and 31 July 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 July and 31 July 2022, there were 2,413 HCP mentions of new pharmaceutical product launches and drug approvals from 1,836 unique HCP authors from around the world.

Click here to read the latest article

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next


What HCPs think about Mixing and Matching Covid-19 vaccines: From rejection to wide acceptance.

03.09.2021 | Article

What HCPs think about Mixing and Matching Covid-19 vaccines: From rejection to wide acceptance.

What HCPs think about Mixing and Matching Covid-19 vaccines

By Maria Aguirre

HCP social media research to support you during COVID-19

19.05.2020 | Article

HCP social media research to support you during COVID-19

The COVID-19 pandemic has radically shifted how we are working and communicating with each o

By Luke Wilson

View all articles >